Paper on Entrainment in Mice by CT1500 Published Paper published on Circadian Entrainmanet in Mice by CT1500 The paper shows in vivo that a single dose of CT1500 enhances re-entrainment to a shifted light dark cycle in a dose-dependent manner in mice and also phase...
Circadian Therapeutics to Attend JP Morgan Healthcare Conference Circadian Therapeutics to attend JP Morgan Healthcare Conference in San Francisco Dr Mark Sampson, CEO will be attending the JP Morgan Healthcare Conference in person from 9th -12th January 2022....
CT1500 Phase 1 Study CT1500 Phase 1 Study Circadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marks move to a clinical stage company • First subject dosed for Phase I study• CT-1500 being developed to treat Non-24 Sleep-Wake...
Circadian Therapeutics and Arquimea Collaboration Circadian Therapeutics and ARQUIMEA sign a collaboration agreement for the development of casein kinase 1 inhibitors for the treatment of diseases affecting the nervous system Co-development of molecules as an...
New CT Research Published Adenosine integrates light and sleep signalling for the regulation of circadian timing in mice New research, published today in Nature Communications by Circadian Therapeutics founders and collaborators, identifies an adenosine-based...
